AI Science Tracker

Discovery of Pyrazolo[3,4-d]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation.

Chinese Academy of Sciences; Shanghai Institute of Materia Medica; State Key Laboratory of Drug Research · 25 Nov 2021 · medicine

Discovery

Discovery of Pyrazolo[3,4-d]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation.

Source check: Source checked. Not independent scientific confirmation.

Finding: A scaffold-design workflow incorporating a deep generative model, kinase screening and docking produced compound 2, with DDR1 IC50 10.6 ± 1.9 nM and selectivity tested against 430 kinases. Cell and mouse-colitis results are preclinical; sample sizes and comparators were not assessed from the abstract.

Technology: Deep generative molecular model

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
The publisher abstract identifies a deep generative model within a scaffold-design workflow with kinase selectivity screening and docking; its specific operation was not assessable from the abstract.
Test and result
The publisher abstract reports DDR1 IC50 10.6 ± 1.9 nM, selectivity testing against 430 kinases, cell cytokine/autophosphorylation assays and a DSS-induced mouse colitis model. Sample sizes and comparator details were not available in the reviewed abstract.
Limitation / still unknown
Only the publisher abstract and metadata were reviewed. Animal sample size, comparator regimen, detailed assay design and the generator's specific operation were not assessed; mouse results do not establish clinical efficacy.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.1021/acs.jmedchem.1c01205

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 18 Nov 2026. Review scope: Indexed primary ACS abstract, supporting-information inventory and online/issue metadata; complete article body not reviewed..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.